Impotence is a common problem
among men characterized by the
consistent inability to sustain an
erection sufficient for sexual
intercourse or the inability to achieve
ejaculation, or both. Erectile
dysfunction can vary. It can involve a
total inability to achieve an erection or
ejaculation, an inconsistent ability to
do so, or a tendency to sustain only
very brief erections.

The risk of impotence increases with
age. It is four-fold higher in men in
their 60s compared with those in their
40s according to a study published in
the Journal of Urology.

In April 2012 the U.S. Food and Drug
Administration  approved Stendra
(avanafil), a new drug to treat erectile
dysfunction, from California based

Erectile dysfunction is when a man has
trouble getting or keeping an erection.

An estimated 30 million men in the
United States are affected by erectile

Stendra is a pill that patients take on
an as-needed basis 30 minutes before
sexual activity. Researchers who
studied Stendra have said the drug
worked within 15 minutes of taking the
medication in some patients, which is
potentially faster than other marketed

Doctors should prescribe the lowest
dose of Stendra that provides benefit.

Stendra belongs to a class of drugs
called phosphodiesterase type 5
(PDE5) inhibitors, which are used to
help increase blood flow to the penis.
As with other PDE5 inhibitors, Stendra
should not be used by men who also
take nitrates, commonly used to treat
chest pain (angina), because the
combination can cause a sudden drop
in blood pressure.

Stendra's safety and efficacy were
established in three double-blind,
placebo-controlled clinical studies. A
total of 1,267 patients were randomly
assigned to take Stendra for up to 12
weeks at doses of 50 milligrams (mg),
100 mg or 200 mg, or a placebo as
needed about 30 minutes before
sexual activity.

The drug falls into the same class as
other erectile-dysfunction treatments
on the market, such as Pfizer Inc.'s
Viagra and Eli Lilly & Co.'s Cialis and
Levitra, marketed by Bayer AG and
GlaxoSmithKline.The drugs work by
increasing blood flow.

World-wide sales of ED drugs
exceeded $5 billion last year,
according to Vivus.

Atherosclerosis effects not only the
arteries but the penile drainage
system. Thus improving arterial flow
may allow the male to have a good
erection, but fail to maintain it long
enough for successful intercourse.

In October 2011   Medtronic has
announced that have conducted a trial
of a drug eluting stent to cure
impotence. These are similar to the
stents used to treat persons with
myocardial infarction (a heart attack).
A catheter is inserted through the
groin and then into the penile artery.
The blockage is identified, cleaned out
and the stent placed to prevent it from
recurring. This is a logical approach to
vascular impotence.  About 50 males
were included in the exploratory trial.

This isn't stenting the penis, but rather
the pudendal artery, which is located in
the pelvis.

The clinical trial was the first to test
stents for treating impotence in men
who don’t respond to drug therapy.

The study found 68 percent
improvement in erectile function after
three months in 30 men with an
average age of 60 who were implanted
with the stents. Their impotence was
caused by narrowed pudendal arteries
in the pelvis. There were no issues
such as clots or the need for surgery
one month after treatment in the study
funded by Minneapolis-based

An inhaler that can help a man get an
erection in just ten minutes.
The inhaler contains a powdered form
of a drug called apomorphine, which
works by stimulating chemical
receptors in the brain.
Although it is still undergoing trials, the
new device - which resembles an
asthma inhaler - could prove popular
with men affected by erectile
dysfunction and represent a
competition to Viagra.

Drugs such as Viagra and similar
medications, including Cialis and
Levitra, have transformed treatment of
impotence in the past ten years.

But around 30 per cent of men who
take them see little or no improvement
in their condition

Apomorphine was developed to treat
Parkinson's disease.  But researchers
noticed it had an ability to boost a
man's desire.

A recent study, published in the
Journal of Sexual Medicine, showed
the majority of the 600 men using an
inhaler of the powdered drug could get
an erection within ten minutes.
Vectura Ltd, (UK) the Wiltshire-based
firm developing the inhaler, hopes it
will one day rival Viagra as a first-line
treatment for impotent men.